Galmed Pharmaceuticals Ltd. (GLMD)Healthcare | Biotechnology | Ramat Gan, Israel | NasdaqCM
0.54 USD
-0.02
(-4.143%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 0.54 +0.01 (1.490%) ⇧ (July 13, 2026, 6:12 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:27 a.m. EDT
The immediate outlook is clouded by a weak statistical forecast predicting a further decline over the next month, yet the recent price action shows a tentative bounce off key support levels, suggesting a potential short-term stabilization rather than an immediate crash. However, the long-term picture is severely compromised by a brutal nine-year trajectory where the asset has lost nearly 99.76% of its value, driven by seven consecutive years of negative annual returns. This persistent multi-year decline indicates a fundamental structural deterioration that outweighs any temporary recovery in sentiment or recent news about acquisitions. The company is burning through cash with negative free cash flow and negative returns on equity, while trading at a fraction of its book value, signaling that the market has priced out the business entirely. With no dividend history to provide income and a balance sheet showing significant operational losses, there is no safety net for investors. The combination of a collapsing business model, a decade-long price implosion, and zero income generation makes this a clear avoidance candidate. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.067076 |
| AutoETS | 0.067077 |
| MSTL | 0.068907 |
| AutoARIMA | 0.074695 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 0.96 |
| Ljung-Box p | 0.004 |
| Jarque-Bera p | 0.364 |
| Excess Kurtosis | 0.76 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 3,542,694 |
| Forward P/E | -0.52 |
| Beta | 0.74 |
| Website | https://galmedpharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.73205745 |
| Address1 | 16 Abba Hillel Road |
| All Time High | 4,870.8 |
| All Time Low | 0.411 |
| Ask | 0.6468 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 110,590 |
| Average Daily Volume3 Month | 544,065 |
| Average Volume | 544,065 |
| Average Volume10Days | 110,590 |
| Beta | 0.743 |
| Bid | 0.385 |
| Bid Size | 2 |
| Book Value | 2.113 |
| City | Ramat Gan |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.5368 |
| Current Ratio | 7.709 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.55 |
| Day Low | 0.49 |
| Display Name | Galmed Pharmaceuticals |
| Earnings Timestamp End | 1,756,756,800 |
| Earnings Timestamp Start | 1,756,238,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | -11,908,306 |
| Eps Forward | -1.03 |
| Eps Trailing Twelve Months | -2.06 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 3 693 8447 |
| Fifty Day Average | 0.60156 |
| Fifty Day Average Change | -0.06475997 |
| Fifty Day Average Change Percent | -0.10765339 |
| Fifty Two Week Change Percent | -73.20574 |
| Fifty Two Week High | 2.34 |
| Fifty Two Week High Change | -1.8031999 |
| Fifty Two Week High Change Percent | -0.7705983 |
| Fifty Two Week Low | 0.411 |
| Fifty Two Week Low Change | 0.12580001 |
| Fifty Two Week Low Change Percent | 0.30608276 |
| Fifty Two Week Range | 0.411 - 2.34 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,394,717,400,000 |
| Float Shares | 6,386,353 |
| Forward Eps | -1.03 |
| Forward P E | -0.5211651 |
| Free Cashflow | -4,989,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 3 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03296 |
| Held Percent Institutions | 0.01923 |
| Implied Shares Outstanding | 6,599,654 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,976,000 |
| Last Split Factor | 1:12 |
| Long Business Summary | Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. |
| Long Name | Galmed Pharmaceuticals Ltd. |
| Market | us_market |
| Market Cap | 3,542,694 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_114779940 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -11,115,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,244,682 |
| Open | 0.55 |
| Operating Cashflow | -7,684,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 3 693 8448 |
| Post Market Change | 0.007999957 |
| Post Market Change Percent | 1.4903048 |
| Post Market Price | 0.5448 |
| Post Market Time | 1,783,980,776 |
| Previous Close | 0.56 |
| Price Hint | 4 |
| Price To Book | 0.2540464 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.649 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0232 |
| Regular Market Change Percent | -4.14285 |
| Regular Market Day High | 0.55 |
| Regular Market Day Low | 0.49 |
| Regular Market Day Range | 0.49 - 0.55 |
| Regular Market Open | 0.55 |
| Regular Market Previous Close | 0.56 |
| Regular Market Price | 0.5368 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 67,666 |
| Return On Assets | -0.33455002 |
| Return On Equity | -0.72116995 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 6,599,654 |
| Shares Percent Shares Out | 0.0097 |
| Shares Short | 74,316 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 17,120 |
| Short Name | Galmed Pharmaceuticals Ltd. |
| Short Percent Of Float | 0.0099 |
| Short Ratio | 0.06 |
| Source Interval | 15 |
| Symbol | GLMD |
| Total Cash | 15,451,000 |
| Total Cash Per Share | 2.341 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.835025 |
| Two Hundred Day Average Change | -0.298225 |
| Two Hundred Day Average Change Percent | -0.35714498 |
| Type Disp | Equity |
| Volume | 67,666 |
| Website | https://galmedpharma.com |
| Zip | 5,250,608 |